Trademark: 90244106
Word
YIPSCELL
Status
Registered
Status Code
700
Status Date
Tuesday, May 31, 2022
Serial Number
90244106
Registration Number
6747871
Registration Date
Tuesday, May 31, 2022
Mark Type
4000
Filing Date
Friday, October 9, 2020
Published for Opposition
Tuesday, December 14, 2021

Trademark Owner History
CiSTEM Inc. - Original Registrant

Classifications
5 pharmaceutical preparations for the treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; biochemical preparations for medical purposes, namely, for the diagnosis and treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; pharmaceutical preparations for the treatment of viral and infectious diseases, autoimmune diseases, kidney diseases, hepatic diseases, neurological diseases and bone diseases; stem cells for medical and veterinary purposes; cultured cells comprised of stem cells for medical use, namely, injection and impanation for treatment of cartilage and meniscus injuries; cells for medical use; cellular function activating agents for medical purposes; cell growth media for growing cells for medical use; reagent kits for medical purposes comprising chemical agents, skin, cartilage and other cells; culture media for cultivating human cells for use in augmentation of bone and other tissues for medical purpose using induced pluripotent cells and embryonic stem-like cells and other stem cells; kit containing chemical media additives being cell growth media for growing cells for medical and veterinary purposes; culture media for cultivating human cells for use in regenerative medicine, oncology, hepatology and hematology; chemical, biochemical, biological, and cell biological products for medical purposes, namely, induced pluripotent stem cells (iPSCs), cell media, cell culture supplements and reagents for cell suspension, cell growth and cell storage; medicines, pharmaceutical products and preparations for health care, namely, induced pluripotent stem cells (iPSCs) and iPSC cultures; cell cultures and cell culture systems for human cells and for medical purposes, namely, induced pluripotent stem cells (iPSCs) and freeze-conserved cells, and reagents for sub cultivation of the cells; intestinal epithelial cell preparations for the treatment of gastrointestinal diseases; pharmaceutical preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; medicinal preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; intestinal epithelial cells for medical purposes; pharmaceutical preparations, namely, live cells in the nature of smooth muscle cells, skeletal muscle cells, myocytes, fibroblasts, chondrocytes, adipocytes, fibromyoblasts, ectodermal cells, hepatocytes, organ cells, liver cells, kidney cells, cardiac cells, pancreatic islet cells, cells present in the intestine, stem cells, osteoblasts, cells forming bone or cartilage, hematopoietic cells, parenchymal cells, stroma cells, totipotent cells (iTC), pluripotent cells (iPSC), and progenitor cells (iMSC) for medical purposes; biological implants, namely, live tissue intended for subsequent implantation; pharmaceutical preparations and drug delivery systems comprising chemical agents and stem cells for the treatment of osteoarthritis, cartilage defects, and cartilage injury; cells, epithelial cells, organoids and cell cultures for personalised medicine, namely, for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; modified stem cells suitable for use as pharmaceutical biologicals used to regenerate neural and spinal cord tissues in humans
42 stem cell research services; research and development services in the field of cytology; custom cell culturing services for scientific and research purposes; testing, inspection, research and development of cell and tissue culturing; research and development of medicines; scientific investigations for medical purposes; custom design and development of chemical reagents scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, solid state characterization; scientific and technological services, namely, scientific research, development, analysis, testing, and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nanoparticle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; biotechnology research; medical research and development in the field of tissue and cell fabrication; biologic services in the nature of biologic research; biomedical services, namely, laboratory services for human tissue, blood, blood components and stem cells for medical use; medical and scientific laboratory services, namely, development of induced pluripotent stem cells using cells derived from healthy and ill humans; medical and scientific laboratory services, namely, development of induced pluripotent stem cell lines using customized primary cells; medical and scientific laboratory services, namely, evaluating of drugs capable of differentiating various serovars suitable for diseases using induced pluripotent stem cells; medical and scientific laboratory services, namely, evaluating of drug efficacy for technology for making animal models of various diseases; medical and scientific laboratory services, namely, evaluating of the quality of induced pluripotent stem cells; medical services, namely, research services relating to stem cells; research, development and testing services for others in the fields of genomics, biotechnology, chemistry and pharmaceuticals; conducting clinical trials for others in the field of stem cell based therapies and products; scientific research services, namely, tracking, analyzing, forecasting, and reporting data in the field of clinical trials of stem cell based therapies and products
YIPS CELL

Trademark Events
May 31, 2022
Notice Of Registration Confirmation Emailed
May 31, 2022
Registered-Principal Register
Apr 23, 2022
Notice Of Acceptance Of Statement Of Use E-Mailed
Apr 22, 2022
Allowed Principal Register - Sou Accepted
Apr 22, 2022
Statement Of Use Processing Complete
Apr 11, 2022
Use Amendment Filed
Apr 22, 2022
Case Assigned To Intent To Use Paralegal
Apr 11, 2022
Teas Statement Of Use Received
Feb 8, 2022
Noa E-Mailed - Sou Required From Applicant
Dec 14, 2021
Official Gazette Publication Confirmation E-Mailed
Dec 14, 2021
Published For Opposition
Nov 24, 2021
Notification Of Notice Of Publication E-Mailed
Nov 9, 2021
Approved For Pub - Principal Register
Nov 8, 2021
Examiner's Amendment Entered
Nov 8, 2021
Notification Of Examiners Amendment E-Mailed
Nov 8, 2021
Examiners Amendment E-Mailed
Nov 8, 2021
Examiners Amendment -Written
Nov 5, 2021
Teas/Email Correspondence Entered
Nov 4, 2021
Correspondence Received In Law Office
Nov 4, 2021
Teas Response To Office Action Received
Oct 23, 2021
Notification Of Non-Final Action E-Mailed
Oct 23, 2021
Non-Final Action E-Mailed
Oct 23, 2021
Non-Final Action Written
Oct 19, 2021
Previous Allowance Count Withdrawn
Oct 12, 2021
Withdrawn From Pub - Og Review Query
Sep 27, 2021
Approved For Pub - Principal Register
Sep 24, 2021
Teas Change Of Correspondence Received
Sep 24, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Sep 24, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 4, 2021
Teas Change Of Correspondence Received
Aug 4, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Aug 4, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jul 28, 2021
Teas/Email Correspondence Entered
Jul 28, 2021
Correspondence Received In Law Office
Jul 28, 2021
Teas Response To Office Action Received
Apr 1, 2021
Notification Of Non-Final Action E-Mailed
Apr 1, 2021
Non-Final Action E-Mailed
Apr 1, 2021
Non-Final Action Written
Mar 9, 2021
Assigned To Examiner
Nov 24, 2020
New Application Office Supplied Data Entered In Tram
Oct 13, 2020
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24